Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CSL360
- Development stage
- Phase 1
- Lead developer
- CSL
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
CSL360 is a recombinant, chimeric immunoglobulin G1 (IgG1) monoclonal antibody that targets the interleukin-3 receptor alpha chain (CD123/IL-3Rα), which is upregulated on leukemic stem cells and blasts in acute myeloid leukemia (AML). By binding to CD123, CSL360 neutralizes IL-3 signaling and demonstrates anti-leukemic activity. It was developed for the treatment of AML by targeting leukemic stem cells that express high levels of CD123. The drug was initially developed by CSL Limited[1][2][7].
- Other names
- anti-IL-3Rα monoclonal antibody
02
Targets
IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on CSL360.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSL360.